Senti Biosciences Holdings (SNTI) Stock News

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company developing Gene Circuit-based cell and gene therapies, has appointed Bryan Baum to its Board of Directors. Baum, Co-Founder and Managing Partner of K5 Global, brings extensive entrepreneurial and investment experience with investments in major companies like SpaceX, OpenAI, and Uber.

As a serial entrepreneur, Baum has founded and successfully sold multiple companies, including Parrot (sold to Filevine), Blue Vision Labs (sold to Lyft), and Represent.com (sold to CustomInk). His expertise in scaling successful companies and strategic insights will support Senti Bio's development of Logic Gated cell therapies for cancer treatment.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, participated in Nasdaq's Amplify Spotlight Series. CEO and Co-Founder Timothy Lu presented a corporate overview highlighting the company's proprietary Gene Circuit platform for developing next-generation cell and gene therapies.

The company's lead program, SENTI-202, is a first-in-class off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3-expressing hematologic malignancies, including AML and myelodysplastic syndrome (MDS). The therapy is currently in Phase 1 clinical trials and has shown positive preliminary data. Notably, SENTI-202 has received Orphan Drug Designation from the FDA for treating relapsed/refractory hematologic malignancies including AML.

Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will present at the 2025 SEED Conference in Houston, TX. The company's Co-Founder and CEO, Timothy Lu, MD, PhD, will deliver a presentation titled "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells" on June 24, 2025 at 1:20 PM CT.

The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals that has attracted over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology.

Senti Biosciences (NASDAQ: SNTI) has received FDA Orphan Drug Designation for SENTI-202, their first-in-class off-the-shelf Logic Gated CAR NK cell therapy targeting acute myeloid leukemia (AML). SENTI-202 is designed to selectively target CD33 and/or FLT3-expressing hematologic malignancies while protecting healthy bone marrow cells. The therapy is currently in Phase 1 clinical trials. AML affects approximately 20,800 newly diagnosed patients annually in the U.S., with a 60% relapse or death rate within 12 months and a median survival rate of 5.3 months for relapsed/refractory cases. The Orphan Drug Designation provides several benefits including tax credits, FDA fee exemptions, and potential seven-year market exclusivity upon approval.

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotech company focused on Gene Circuit platform cell and gene therapies, has granted stock options to eight new employees. The Board approved options to purchase 102,500 shares at an exercise price of $3.03 per share on June 3, 2025. These inducement equity awards were granted under the company's Amended and Restated 2022 Inducement Equity Plan, which was initially adopted on August 5, 2022. The grants were made in accordance with NASDAQ Listing Rule 5635(c)(4) as material inducement for the new employees joining the company.

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotech company focused on developing next-generation cell and gene therapies through its Gene Circuit platform, has announced its participation in a Virtual Fireside Chat hosted by Chardan Capital Markets. The event will take place on Monday, June 9, 2025, at 3:00 PM ET. Key participants include CEO and Co-Founder Timothy Lu, M.D., Ph.D., President and CMO Kanya Rajangam, M.D., Ph.D., and CFO Jay Cross, who will engage in a moderated discussion with Chardan's senior research analyst, Geulah Livshits, Ph.D.

Senti Biosciences (NASDAQ: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its proprietary Gene Circuit platform, has announced an upcoming presentation. Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, will present at the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Thursday, May 29, 2025, at 2:40 PM ET.

Senti Biosciences (NASDAQ: SNTI) has received an additional $1.0 million from the California Institute for Regenerative Medicine (CIRM) after achieving clinical study enrollment milestones. This brings the total received to $7.4 million of the $8.0 million grant supporting SENTI-202 development.

SENTI-202, a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, targets CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells. In its ongoing Phase 1 trial, preliminary results showed the therapy was well-tolerated with no dose-limiting toxicities. The preliminary recommended Phase 2 dose was set at 1.5 x 109 CAR NK cells.

Notable efficacy results include: 2 of 3 patients achieving composite Complete Remission (cCR) in the preliminary RP2D cohort, 5 of 7 patients achieving Overall Response Rate across all dose levels, and 4 of 4 cCR patients achieving MRD-negative status, with the longest response lasting 8+ months.

Senti Biosciences (SNTI) has released a mechanism of action video for SENTI-202, their first-in-class off-the-shelf CAR NK cell therapy. The therapy targets CD33 and/or FLT3-expressing hematologic malignancies like AML and MDS. SENTI-202 features three key components: an OR Logic Gate targeting leukemia cells, a NOT Logic Gate protecting healthy cells, and calibrated IL-15 release enhancing immune response. The ongoing Phase 1 trial shows promising results with no dose-limiting toxicities. At the preliminary recommended Phase 2 dose, 2 of 3 patients achieved complete remission. Overall, 5 of 7 evaluable patients showed response, with 4 achieving complete remission. All complete remission patients remain in remission with 4+ to 8+ months of follow-up.